Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and CAR T-cell Therapy in Relapsed/Refractory PMBCL
NCT05934448Phase 2Recruiting
- Start
- Nov 2023
- Primary completion
- Jun 2027
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in primary mediastinal large B-cell lymphoma (PMBCL), diffuse large B-cell lymphoma (DLBCL), T-cell/histiocyte-rich large B-cell lymphoma (THRLBCL). Started Nov 2023; status: recruiting.
02
Drugs
03
Conditions
primary mediastinal large B-cell lymphoma (PMBCL)diffuse large B-cell lymphoma (DLBCL)T-cell/histiocyte-rich large B-cell lymphoma (THRLBCL)
Beyond the preview
Go deeper on NCT05934448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05934448.